A first-in-human, randomized, double-blind, placebo-controlled, 3-part study assessing the safety, tolerability, pharmacodynamics and pharmacokinetics of GL0071 after single and repeated ascending subcutaneous doses in healthy normal weight, overweight and obese participants, as well as a 12-week treatment randomized, double blind, placebo-controlled exploratory Proof-of-Concept study in overweight and obese participants.
This is a Phase 1 clinical trial testing a new experimental medicine called GL0071. Because this is a 'first-in-human' trial, it is the first time the medicine is being given to people. The main goal is to find out if the drug is safe, what side effects it might cause, and how it behaves inside the body. The trial also looks at whether GL0071 might help treat type 2 diabetes and manage body weight. It involves healthy adults of normal weight, as well as people who are overweight or living with obesity. Participants will receive GL0071 or a dummy medicine (a placebo) as an injection just under the skin. Some people will receive only one dose, while others will take part in a 12-week treatment course to see how well the medicine works over time.
At a glance
What is this study about?
Type 2 diabetes and excess body weight are closely linked and affect millions of people across the UK. Over time, high blood sugar and excess weight can increase the risk of heart disease, kidney issues, and other long-term problems. Scientists are constantly searching for new, more effective treatments to help people manage their blood sugar and weight safely.
This study focuses on a new investigational drug called GL0071. It is a Phase 1 clinical trial, which means it is the very first step in testing the medicine in human volunteers. The main priority at this stage is safety. Researchers need to see how the human body absorbs, processes, and clears the drug, and whether it causes any unwanted side effects as the doses are gradually increased.
The trial is split into different stages. First, small groups receive a single dose to check that it is well tolerated. Later stages test repeated doses, and one part of the trial follows overweight or obese volunteers over a 12-week period to see if the drug shows early signs of helping with weight and metabolism.
To ensure fair and reliable results, the study is 'double-blind' and 'placebo-controlled'. This means some participants receive a harmless dummy injection instead of the active medicine, and neither the participants nor the clinic doctors will know who received which until the study ends.
Key takeaways
- Tests a new medicine called GL0071 for the first time in human volunteers.
- Aimed at finding new ways to help manage type 2 diabetes and body weight.
- Includes healthy adults as well as people who are overweight or have obesity.
- The medicine is given as an injection just under the skin.
- Taking part is voluntary, closely monitored by doctors, and you can withdraw at any time.
Who may be eligible?
This trial is open to adults aged 18 and older. Because the study has several parts, researchers are looking for a few different groups of people. This includes healthy volunteers with a normal body weight, as well as adults who are overweight, living with obesity, or diagnosed with type 2 diabetes.
To take part, you must be generally well enough to join an early-stage medicine study. The study team will carry out health checks, such as blood tests, urine tests, and heart tracings, to ensure taking part is safe for you.
You may not be able to join if you have certain severe medical conditions, a history of major organ disease, or known allergies to the study ingredients. Women who are pregnant, breastfeeding, or planning a pregnancy will not be eligible, as the effects of the new drug on unborn babies are not yet known.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I am of normal weight, overweight, or have been diagnosed with type 2 diabetes.
- I am comfortable receiving injections under the skin.
- I am willing to attend regular clinic visits and possible overnight stays.
- I am not pregnant, breastfeeding, or planning a pregnancy during the study.
What does participation involve?
Taking part involves visiting a specialist clinical trial clinic. Before anything begins, you will attend a screening appointment to check your health and confirm your eligibility. If you join, you will receive GL0071 or a placebo via an injection just under the skin (subcutaneous injection). Depending on which part of the study you join, you may receive a single dose, multiple doses over a few weeks, or treatment for up to 12 weeks. You will need to attend regular clinic visits for blood tests, blood pressure checks, heart monitoring (ECGs), and health questionnaires. Some parts of the study may require you to stay overnight at the clinic so the medical team can monitor you closely. After your treatment ends, there will be follow-up visits to check your recovery.
Potential risks and benefits
Locations (1)
- —UnverifiedBelgium
Common questions
What does 'first-in-human' mean?
It means the medicine has been tested in laboratory settings before, but this is the first time it is being given to people. Doses start very low to keep participants safe.
What is a placebo?
A placebo is a dummy treatment that looks identical to the real medicine but contains no active drug. It helps scientists prove whether changes are truly caused by the new medicine.
How is the study medicine given?
The medicine is given as a subcutaneous injection, which means a small needle injects the liquid into the fatty layer just under the skin, often in the tummy or thigh.
Will I be paid for taking part?
Early-phase trials often offer compensation for your time, inconvenience, and travel expenses. The study team will explain the exact details before you agree to join.
Can I leave the study early?
Yes. You have the legal right to leave the study at any point, for any reason, without giving an explanation and without it affecting your future medical treatment.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.